Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Inclusion Criteria:

* Recurrent or persistent cervical cancer after prior systemic chemotherapy for which there is no curative intent option
* Documented histologic cervical cancer (acceptable histologies: squamous carcinoma, adenocarcinoma, and adenosquamous carcinoma)
* Patients must have PD-L1 tumor positivity as defined as CPS\>/= 1
* Age greater than 18 and ECOG performance status of \<= 2
* Adequate organ and marrow function

Exclusion Criteria:

* Prior treatment with cabozantinib or pembrolizumab
* Receipt of any type of small molecule kinase inhibitor
* Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy
* Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment
* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery
* Anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel)
* Uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions: Cardiovascular disorders: Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias Uncontrolled hypertension despite optimal antihypertensive treatment, stroke
* Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation
* Clinically significant hematuria, hematemesis, or hemoptysis of \> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage) within 12 weeks before first dose
* Active autoimmune disease requiring systemic therapy within the past 2 years
* Active infection requiring systemic therapy within the past month
* History of immunodeficiency